A recent analysis published in BMJ Open Diabetes Research & Care revealed that reducing albuminuria plays a crucial role in improving long-term outcomes for patients living with chronic kidney disease and type 2 diabetes mellitus. The study demonstrated that patients who achieved a sustained decrease of more than thirty percent in the urine albumin-to-creatinine ratio over a period of six to twenty-four months experienced significantly lower risks of death, cardiovascular events, and kidney disease progression. These results highlight that albuminuria is not only a marker of kidney damage but also a modifiable treatment target capable of influencing overall survival. Researchers found that consistent albuminuria monitoring provided valuable insights into disease trajectory and treatment

See Full Page